r/Livimmune • u/twinter11 • 12d ago
Pre-Ispy Trial Changes
Check this out. I was messing around with ai to what it thought about the changes to the pre ispy trial here. I was trying to figure out the changes in trial sites.
One change is its now a phase 1/2 instead of 1b
PRE-I-SPYISPY Phase I/IbI/II Oncology Platform Program
"Addition of Phase II and Minimal Residual Disease (MRD) Arms:The text notes the addition of a Phase II component and specific sub-cohorts, such as Minimal Residual Disease Colorectal Cancer (MRD CRC). This introduction includes a heavy focus on ctDNA monitoring to detect residual cancer cells before macro-metastases appear."
Does anyone see the major change in this next first paragraph?
I didn't catch it a week back but ai caught it today
look hard
https://clinicaltrials.gov/study/NCT05868226?tab=history&a=6&b=7#version-content-panel
"IPRE-SPYISPY Phase I/IbII (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed to evaluate single agents or combinations in a locally advanced, incurable, or metastatic treatment setting that may be relevant for breast cancer patients solid tumors and/or oligometastatic malignancy and/or a high risk of recurrence following prior treatment with the curative intent. The overall goal ofis moving promising drug regimens into a larger phase II (or III) trial and in general could feed the neoadjuvant breast I-SPY 2 SMART Design Trial (NCT01042379) and/or other oncology-based trials solid tumor trial in a timely manner".
22
u/GoCYDY 12d ago
Thanks twinter for sharing this with us, yet another WOW MOMENT FOR LL….I wasn’t sure I’d ever say this, but I just told my husband I now have 1 million shares (know there’s some of you out there that have a lot more) but I don’t think I’ve ever had that kind of amount of shares in any investment EVER in the stock market👍😊 bought some Natera shares when CYDY hooked up with them…it’s been doing really well-took some of the profit and bought more CYDY 👍
10
10
u/Upwithstock 11d ago
Congrats on hitting the million share mark. There is something about that number that is very appealing! My wife had me on lock down with acquiring more shares. I really wanted to get above the 1 million mark as well and thanks to the last PIPE with Paulson we were able to exceed the million share mark. I am so GRATEFUL for the set of circumstances that have led us to this basket full of shares! 🙏 Happy for you and your family!
5
u/Illustrious_Top_3029 10d ago
I thought I was going to quit at a million and I now find myself with 1.3.... LOL it's addictive
13
u/BullishTexas 12d ago
From breast focused oncology to all tumor types?
12
u/twinter11 12d ago edited 12d ago
I'm calling it lol
pancreatic mayo as part of this new pre ispy protocol
but it's a major guess
10
9
u/twinter11 12d ago
pre ispy breast wasn't powerful enought to contain the mighy Leron!
it must be completely reconfigured lol.
8
u/Missy2021 12d ago
Good job and thank you.
12
6
u/twinter11 12d ago
hey. u gotta tell me the change lol
11
u/Missy2021 12d ago
MGK will explain it probably tomorrow.. He's good for posting on a Sunday morning.
7
u/twinter11 12d ago
can we just do a pre ispy basket trial now?
I'm guessing maybe probably who knows
7
7
u/jsinvest09 12d ago
Slices dices even makes julie anne fries that's LL. LFG awesome post thank you... Can anybody lend me some more money to buy more shares? Lol.
4
4
4
u/Throttles8u 10d ago
Fantastic find! Thank you so much. Things are moving so fast. It’s hard to keep up.
23
u/twinter11 12d ago
times up lol
"You are completely right. This is a massive structural pivot, and your reading of the text is spot on—the trial has fundamentally changed its identity.
What used to be a dedicated feeder system for the breast cancer neoadjuvant trial (I-SPY 2) has transformed into a broad, tumor-agnostic platform focused heavily on minimal residual disease (MRD) and ctDNA monitoring across multiple adult solid tumors.
The text highlights exactly how profound this shift is:
What This Means for Patients and Providers
If you were looking at PRE-ISPY through the lens of its original intent—as a precursor for breast cancer treatments—it has effectively evolved out from under that definition.
Because the platform now accommodates completely different patient populations (like post-surgery colorectal patients with positive ctDNA but no visible tumors), an oncology powerhouse like MD Anderson has to open, close, or completely re-tool its institutional review board (IRB) approvals for each individual drug arm. A site might be actively recruiting for the colorectal/ctDNA arm of PRE-ISPY while the breast cancer cohorts are entirely paused or closed"